Claims
- 1. A compound of the formula (I):
- 2. The compound or the pharmaceutically acceptable salt of claim 1, wherein R1 represents a hydrogen atom or a chlorine atom.
- 3. The compound or the pharmaceutically acceptable salt of claim 1, wherein R1 represents a chlorine atom.
- 4. The compound of claim 1 which is 5-amino-6-chloro-2-methyl-N-(piperidin-4-ylmethyl)imidazo[1,2-a]pyridine-8-carboxamide, or a pharmaceutically acceptable salt thereof.
- 5. The compound of claim 1 which is 5-amino-6-chloro-2-ethyl-N-(piperidin-4-ylmethyl)imidazo[1,2-a]pyridine-8-carboxamide, or a pharmaceutically acceptable salt thereof.
- 6. A pharmaceutical composition for the treatment of disease conditions mediated by 5-HT4 receptor activities and/or 5-HT3 receptor activity, in a mammalian subject, comprising a therapeutically effective amount of a compound of formula (I):
- 7. A pharmaceutical composition of claim 5, wherein the disease condition is selected from gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome, constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorder, anxiety, psychoses, depression, gastrointestinal motility disturbancies, diarrhea, diseases characterized by delayed gastric emptying, ileus, ischaemic stroke and diabetes.
- 8. A method for the treatment of disease conditions mediated by 5-HT4 receptor activity and/or 5-HT3 receptor activity, in a mammalian subject, which comprises administering to said subject a therapeutically effective amount of a compound of the formula (I):
- 9. A method of claim 8, wherein the disease condition is selected from gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome, constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorder such as cardiac failure and heart arrhythmia, anxiety, psychoses, depression, gastrointestinal motility disturbancies, diarrhea, diseases characterized by delayed gastric emptying, ileus, ischaemic stroke and diabetes.
RELATED APPLICATIONS
[0001] This application claims benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/464,263, filed Apr. 21, 2003, which is incorporated herein in its entirety by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60464263 |
Apr 2003 |
US |